Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two drugs: - **Hydrocortisone** (marketed as Alkindi Sprinkle with the imprint "INF-2.0") is a synthetic glucocorticoid used primarily for adrenocortical insufficiency and other conditions requiring corticosteroid therapy. It acts by mimicking endogenous cortisol, exerting anti-inflammatory and immunosuppressive effects through binding to the glucocorticoid receptor. - **Ibuprofen** is a nonsteroidal anti-inflammatory drug (NSAID) widely used for pain relief, fever reduction, and inflammation control. It works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis. No evidence was found that "INF2.0 + ibuprofen" exists as a marketed fixed-dose combination product; this entry describes the theoretical or compounded use of both agents together.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone + ibuprofen.